Abstract 93P
Background
Urothelial carcinoma (UC) is a prevalent malignancy in the urinary system, which consists of approximately 82% of bladder cancer and 18% upper tract urothelial carcinomas (UTUCs) in China. The diagnosis of UC poses significant challenges due to the invasiveness of cystoscopy and the limited sensitivity of cytology. Therefore, there is a pressing clinical demand for developing more sensitive and non-invasive diagnostic techniques to complement the existing approaches.
Methods
In this study, we conducted a comprehensive analysis utilizing methylation data from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) database, and a cohort from Renji Hospital. These datasets served as discovery cohorts for the identification of UC-specific methylation markers. Urine samples from 180 cases were collected as a training cohort. Quantitative methylation-specific PCR was performed on these samples, followed by logistic regression for constructing a diagnostic model. The model's performance was further validated in a prospective cohort comprising 508 cases.
Results
Our analysis of the discovery cohort identified three significant methylation markers. UriMee, a diagnostic model, based on two urine-based methylation markers in the training cohort (65 UC cases vs. 115 non-UC cases), exhibited remarkable performance with an area under the curve (AUC) of 0.96. In the independent validation cohort (154 UC cases vs. 354 non-UC cases), UriMee demonstrated a sensitivity of 91% and a specificity of 93% (AUC=0.94). Notably, for early-stage (Ta-1) cases, the sensitivity reached 87%. Moreover, a significant correlation was observed between the UriMee detection values and tumor grade, with an 81% sensitivity for detecting low grade cases. UriMee also demonstrated high accuracy, reaching 91%, in diagnosing UTUCs.
Conclusions
UriMee holds significant promise as a non-invasive urine-based testing method, which has the potential to greatly enhance the early diagnosis of UC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
Presenter: Li Lin
Session: Poster session 07
32P - Patient derived circulating tumor cell clusters for personalized chemotherapy
Presenter: Prashant Kumar
Session: Poster session 07
Resources:
Abstract
33P - Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors
Presenter: Noémie Luong
Session: Poster session 07
34P - A novel gene family underlying cancer cell resilience
Presenter: David Amici
Session: Poster session 07
35P - The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Presenter: Jianhui Ma
Session: Poster session 07
36P - Branched-chain amino acids metabolism reprogramming in trastuzumab primary resistant HER2 positive breast cancer
Presenter: Yijia Hua
Session: Poster session 07
37P - A consensus gene set facilitates enrichment analysis of cancer hallmarks
Presenter: Otília Menyhart
Session: Poster session 07
38P - Feasibility of expanding tumor-infiltrating lymphocytes from cryopreserved tumor specimens after long-term storage
Presenter: Daria Kuznetsova
Session: Poster session 07
39P - Search for rare copy number variants associated with hereditary breast cancer in Finnish case-control cohorts
Presenter: Timo Kumpula
Session: Poster session 07
40P - STOPIN: A new approach to solve the hematological toxicity of antibody-drug conjugates (ADC) with soft topoisomerase inhibitor
Presenter: Xinghai Wang
Session: Poster session 07